<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": italic;} PathogensPathogenspathogensPathogens2076-0817MDPI pmcid: 7350360 doi: 10.3390/pathogens9060430pathogens-09-00430 : Review SARS-CoV-2" exact="Infection" post="and the Liver MorganKatie1*SamuelKay2https://orcid.org/0000-0001-8610-9485VandeputteMartin1HayesPeter C.1https://orcid.org/0000-0001-8863-8778PlevrisJohn N.1[1], M.F.R.Vandeputte@sms.ed.ac.ukP.Hayes@ed.ac.ukJ.Plevris@ed.ac.uk[2], K.Samuel@ed.ac.uk *Correspondence:"/>
 <result pre="(SARS-CoV-2) was reported in Wuhan China in December 2019. Initially," exact="infection" post="presented with a broad spectrum of symptoms which typically"/>
 <result pre="presented with a broad spectrum of symptoms which typically included" exact="muscle" post="aches, fever, dry cough, and shortness of breath. SARS-CoV-2"/>
 <result pre="enters cells via ACE2 receptors which are abundant throughout the" exact="respiratory" post="tract. However, there is evidence that these receptors are"/>
 <result pre="it is questionable if the injury is due to direct" exact="viral" post="damage, drug-induced liver injury, hypoxia, or microthromboses. Likely, the"/>
 <result pre="injury is multifactoral, and management of infected patients with pre-existing" exact="liver disease" post="should be taken into consideration. Ultimately, a vaccine is"/>
 <result pre="is multifactoral, and management of infected patients with pre-existing liver" exact="disease" post="should be taken into consideration. Ultimately, a vaccine is"/>
 <result pre="be addressed. SARS-CoV-2 COVID-19 liver drug induced liver injury microthromboses" exact="viral" post="damage 1. Introduction A novel strain of coronaviridae (SARS-CoV-2)"/>
 <result pre="Previous strains of coronavirus outbreaks in humans include Middle East" exact="Respiratory" post="Syndrome (MERS) in 2012 and Severe Acute Respiratory Syndrome"/>
 <result pre="strains of coronavirus outbreaks in humans include Middle East Respiratory" exact="Syndrome" post="(MERS) in 2012 and Severe Acute Respiratory Syndrome (SARS)"/>
 <result pre="humans include Middle East Respiratory Syndrome (MERS) in 2012 and" exact="Severe" post="Acute Respiratory Syndrome (SARS) in 2003 [5,6]. Similar to"/>
 <result pre="include Middle East Respiratory Syndrome (MERS) in 2012 and Severe" exact="Acute" post="Respiratory Syndrome (SARS) in 2003 [5,6]. Similar to SARS,"/>
 <result pre="Middle East Respiratory Syndrome (MERS) in 2012 and Severe Acute" exact="Respiratory" post="Syndrome (SARS) in 2003 [5,6]. Similar to SARS, SARS-CoV-2"/>
 <result pre="East Respiratory Syndrome (MERS) in 2012 and Severe Acute Respiratory" exact="Syndrome" post="(SARS) in 2003 [5,6]. Similar to SARS, SARS-CoV-2 is"/>
 <result pre="2003 [5,6]. Similar to SARS, SARS-CoV-2 is primarily transmitted by" exact="respiratory" post="droplets produced by infected persons when they sneeze, cough,"/>
 <result pre="saliva, other routes of transmission have been considered [7,8]. COVID-19" exact="disease" post="refers to infection with the SARS-CoV-2 virus. Incubation time"/>
 <result pre="of transmission have been considered [7,8]. COVID-19 disease refers to" exact="infection" post="with the SARS-CoV-2 virus. Incubation time is within 14"/>
 <result pre="(with frequency estimated between 17% and 88% of cases) [10,11,12,13,14]," exact="infection" post="initially presents with a broad spectrum of symptoms that"/>
 <result pre="37 Â°C), dry cough, shortness of breath, anosmia/dysgueusia, headaches, and" exact="muscle" post="aches [7,11,15,16,17]. Some other viral related symptoms, albeit less"/>
 <result pre="of breath, anosmia/dysgueusia, headaches, and muscle aches [7,11,15,16,17]. Some other" exact="viral" post="related symptoms, albeit less common, can also be seenâ€&quot;sore"/>
 <result pre="related symptoms, albeit less common, can also be seenâ€&quot;sore throat," exact="chest" post="pain, nausea, vomiting, diarrhoea, skin rashes, and vasculitic manifestations."/>
 <result pre="chest pain, nausea, vomiting, diarrhoea, skin rashes, and vasculitic manifestations." exact="Severe" post="infection seems to present a biphasic pattern [18,19,20,21]. A"/>
 <result pre="pain, nausea, vomiting, diarrhoea, skin rashes, and vasculitic manifestations. Severe" exact="infection" post="seems to present a biphasic pattern [18,19,20,21]. A first"/>
 <result pre="rashes, and vasculitic manifestations. Severe infection seems to present a" exact="biphasic" post="pattern [18,19,20,21]. A first phase (â€˜viremiaâ€™), corresponding to viral"/>
 <result pre="a biphasic pattern [18,19,20,21]. A first phase (â€˜viremiaâ€™), corresponding to" exact="viral" post="invasion of the body, causes symptoms as described above."/>
 <result pre="(â€˜cytokine stormâ€™), responsible for severe cardiopulmonary manifestations, sometimes leading to" exact="acute" post="respiratory distress syndrome, shock, and death [18,19,20,21]. Respiratory symptoms,"/>
 <result pre="stormâ€™), responsible for severe cardiopulmonary manifestations, sometimes leading to acute" exact="respiratory" post="distress syndrome, shock, and death [18,19,20,21]. Respiratory symptoms, in"/>
 <result pre="leading to acute respiratory distress syndrome, shock, and death [18,19,20,21]." exact="Respiratory" post="symptoms, in particular hypoxia, have been the main indication"/>
 <result pre="seem to occur during either the viremia or inflammatory phase." exact="Reduced" post="albumin can be due to inflammatory response while raised"/>
 <result pre="to date knowledge on liver injury in the context COVID-19" exact="disease" post="in patients with or without pre-existing liver disease. We"/>
 <result pre="the context COVID-19 disease in patients with or without pre-existing" exact="liver disease." post="We also discuss possible mechanisms of liver injury and"/>
 <result pre="or without pre-existing liver disease. We also discuss possible mechanisms" exact="of liver" post="injury and the current advice regarding management of liver"/>
 <result pre="mechanisms of liver injury and the current advice regarding management" exact="of liver" post="disease patients including liver transplant recipients. 2. Viral Entry"/>
 <result pre="of liver injury and the current advice regarding management of" exact="liver disease" post="patients including liver transplant recipients. 2. Viral Entry and"/>
 <result pre="liver injury and the current advice regarding management of liver" exact="disease" post="patients including liver transplant recipients. 2. Viral Entry and"/>
 <result pre="management of liver disease patients including liver transplant recipients. 2." exact="Viral" post="Entry and Effect on Liver SARS-CoV-2 enters the host"/>
 <result pre="known to be abundant in alveolar cells accounting for the" exact="viral" post="injury to lungs of infected patients [22]. While there"/>
 <result pre="cholangiocytes have the same percentage of ACE2 receptors as aveolar" exact="type 2" post="cells [25]. Further, it has been suggested that infection"/>
 <result pre="type 2 cells [25]. Further, it has been suggested that" exact="infection" post="of cholangiocytes may be the source of the virus"/>
 <result pre="or could possibly aid the virus. 3. Possible Causes of" exact="Elevated" post="Liver Enzymes Emerging data for abnormal liver enzymes seen"/>
 <result pre="patients raises several questions. Are these abnormalities due to direct" exact="viral" post="damage, drug-induced liver injury (DILI), unknown pre-existing liver disease,"/>
 <result pre="to direct viral damage, drug-induced liver injury (DILI), unknown pre-existing" exact="liver disease," post="or indirect consequence of viral damage to other systems"/>
 <result pre="injury (DILI), unknown pre-existing liver disease, or indirect consequence of" exact="viral" post="damage to other systems (cardiopulmonary, haemostasis)? Liver samples from"/>
 <result pre="infected patients were examined, and moderate microvascular steatosis with mild" exact="lobular" post="and portal activity were reported [29]. It does seem"/>
 <result pre="that may affect liver function could principally be due to" exact="hypoxia" post="and shock, although a direct effect of SARS-CoV-2 to"/>
 <result pre="or DILI can also be contributing factors [29,30]. 3.1. Direct" exact="Viral" post="Damage While mechanisms of direct damage to the liver"/>
 <result pre="of direct damage to the liver remain unclear, concerns about" exact="viral" post="damage have already been raised, e.g., with a case"/>
 <result pre="have already been raised, e.g., with a case of SARS-CoV-2" exact="infection" post="concurrent with liver failure, without other apparent cause, recently"/>
 <result pre="raised, e.g., with a case of SARS-CoV-2 infection concurrent with" exact="liver failure," post="without other apparent cause, recently described in Germany [31]."/>
 <result pre="other apparent cause, recently described in Germany [31]. However, direct" exact="viral" post="damage has been contested by some, and other explanations"/>
 <result pre="has raised the question of DILI as a possible cause" exact="of liver" post="injury seen in COVID-19 patients. They show that patients"/>
 <result pre="patients given lopinavir or ritonavir after admission presented higher incidence" exact="of liver" post="injury and required longer stay in hospital. It is"/>
 <result pre="to many questions involving the management of SARS-CoV-2 and pre-existing" exact="liver disease." post="3.3. Hypoxic Liver Sepsis complicating severe COVID-19 illness and"/>
 <result pre="disease. 3.3. Hypoxic Liver Sepsis complicating severe COVID-19 illness and" exact="hypoxia" post="can also be significant contributing factors [30]. Hypoxic liver"/>
 <result pre="[35]. This typically occurs in the elderly with right side" exact="congestive heart failure" post="[35]. Though the median age of patients contracting SARS-CoV-2"/>
 <result pre="This typically occurs in the elderly with right side congestive" exact="heart" post="failure [35]. Though the median age of patients contracting"/>
 <result pre="reported that in certain patient groups, often younger patients, micro" exact="vascular" post="thromboses can cause end stage organ damage and may"/>
 <result pre="patient groups, often younger patients, micro vascular thromboses can cause" exact="end stage" post="organ damage and may potentially affect the liver. It"/>
 <result pre="phosphatase have been used as a prognostic value for ischemic" exact="stroke" post="patients and in identifying high risk haemorrhagic transformation and"/>
 <result pre="The liver was described as having hepatocyte degeneration accompanied by" exact="lobular" post="focal necrosis and neutrophil infiltration. Though histological features of"/>
 <result pre="liver was described as having hepatocyte degeneration accompanied by lobular" exact="focal" post="necrosis and neutrophil infiltration. Though histological features of liver"/>
 <result pre="by lobular focal necrosis and neutrophil infiltration. Though histological features" exact="of liver" post="failure and bile duct injuries were not observed in"/>
 <result pre="lobular focal necrosis and neutrophil infiltration. Though histological features of" exact="liver failure" post="and bile duct injuries were not observed in these"/>
 <result pre="in these cases [27]. 3.5. SARS-CoV-2 in Patients with Pre-Existing" exact="Liver Disease" post="Patients with pre-existing conditions have shown increased susceptibility to"/>
 <result pre="these cases [27]. 3.5. SARS-CoV-2 in Patients with Pre-Existing Liver" exact="Disease" post="Patients with pre-existing conditions have shown increased susceptibility to"/>
 <result pre="Pre-Existing Liver Disease Patients with pre-existing conditions have shown increased" exact="susceptibility to" post="SARS-CoV-2. At present, it is unclear to what extent"/>
 <result pre="SARS-CoV-2. At present, it is unclear to what extent pre-existing" exact="liver disease" post="contributes to liver injury seen in SARS-CoV-2 patients. A"/>
 <result pre="At present, it is unclear to what extent pre-existing liver" exact="disease" post="contributes to liver injury seen in SARS-CoV-2 patients. A"/>
 <result pre="UK on more than 17 million people has identified pre-existing" exact="liver disease" post="as an independent risk factor of death in SARS-CoV-2"/>
 <result pre="on more than 17 million people has identified pre-existing liver" exact="disease" post="as an independent risk factor of death in SARS-CoV-2"/>
 <result pre="disease as an independent risk factor of death in SARS-CoV-2" exact="infections" post="[42]. For instance, it has been shown that patients"/>
 <result pre="been shown that patients with SARS-CoV-2 show an increase of" exact="monocyte" post="chemoattractant protein 1 (MCAP1), which is a chemokine known"/>
 <result pre="is a chemokine known to exacerbate steatohepatitis [34]. A recent" exact="short" post="communication describes possible implications for patients with non-alcoholic fatty"/>
 <result pre="A recent short communication describes possible implications for patients with" exact="non-alcoholic fatty liver" post="disease (NAFLD) [43]. NAFLD patients, alongside those with metabolic"/>
 <result pre="recent short communication describes possible implications for patients with non-alcoholic" exact="fatty liver disease" post="(NAFLD) [43]. NAFLD patients, alongside those with metabolic syndrome"/>
 <result pre="short communication describes possible implications for patients with non-alcoholic fatty" exact="liver disease" post="(NAFLD) [43]. NAFLD patients, alongside those with metabolic syndrome"/>
 <result pre="communication describes possible implications for patients with non-alcoholic fatty liver" exact="disease" post="(NAFLD) [43]. NAFLD patients, alongside those with metabolic syndrome"/>
 <result pre="implications for patients with non-alcoholic fatty liver disease (NAFLD) [43]." exact="NAFLD" post="patients, alongside those with metabolic syndrome and type 2"/>
 <result pre="fatty liver disease (NAFLD) [43]. NAFLD patients, alongside those with" exact="metabolic syndrome" post="and type 2 diabetes, are often treated with ACE"/>
 <result pre="liver disease (NAFLD) [43]. NAFLD patients, alongside those with metabolic" exact="syndrome" post="and type 2 diabetes, are often treated with ACE"/>
 <result pre="(NAFLD) [43]. NAFLD patients, alongside those with metabolic syndrome and" exact="type 2" post="diabetes, are often treated with ACE inhibitors, which have"/>
 <result pre="ACE inhibitors up-regulate the ACE2 receptor and therefore can increase" exact="viral" post="load in patients taking these medications [43,44]. NAFLD patients"/>
 <result pre="can increase viral load in patients taking these medications [43,44]." exact="NAFLD" post="patients often exhibit increased cytokine levels due to their"/>
 <result pre="NAFLD patients often exhibit increased cytokine levels due to their" exact="chronic" post="inflammatory stage. Prins and Olinga suggest that this predisposition,"/>
 <result pre="in patients infected with SARS-CoV-2, could expedite the progression of" exact="NAFLD" post="to a more aggressive non-alcoholic steatohepatitis [43]. There is"/>
 <result pre="more aggressive non-alcoholic steatohepatitis [43]. There is suggestion that derangement" exact="of liver" post="function should be taken into consideration alongside other physiological"/>
 <result pre="direct injury from the virus itself, as observed with other" exact="respiratory" post="viruses [11,16,30,45]. Regardless of the source of injury, it"/>
 <result pre="of injury, it is clear that managing those with pre-existing" exact="liver disease" post="needs to be thought out carefully during this pandemic"/>
 <result pre="injury, it is clear that managing those with pre-existing liver" exact="disease" post="needs to be thought out carefully during this pandemic"/>
 <result pre="higher risk of being infected and of more severe COVID-19" exact="disease" post="and should be practising strict social distancing or shielding"/>
 <result pre="called on the UK government to classify those with extreme" exact="liver disease" post="as â€˜extremely vulnerableâ€™ [47]. Recent reports suggest that more"/>
 <result pre="on the UK government to classify those with extreme liver" exact="disease" post="as â€˜extremely vulnerableâ€™ [47]. Recent reports suggest that more"/>
 <result pre="University of North Carolina has shown that those with decompensated" exact="cirrhosis" post="are at most risk and are calling on hospitals"/>
 <result pre="British Liver Trust also suggests that all patients with decompensated" exact="cirrhosis" post="practice social shielding, a step up from social distancing,"/>
 <result pre="published comprehensive recommendations for management and surveillance of patients with" exact="liver disease" post="throughout the SARS-CoV-2 outbreak [28]. This paper now forms"/>
 <result pre="comprehensive recommendations for management and surveillance of patients with liver" exact="disease" post="throughout the SARS-CoV-2 outbreak [28]. This paper now forms"/>
 <result pre="of Liver and the European Society of Clinical Microbiology and" exact="Infectious" post="Disease [49]. They suggest prioritization of outpatient clinics, inpatient"/>
 <result pre="Liver and the European Society of Clinical Microbiology and Infectious" exact="Disease" post="[49]. They suggest prioritization of outpatient clinics, inpatient admission"/>
 <result pre="of patient care weighed against the risk of infection. 4." exact="Disease" post="Severity in the Immunocompromised and Transplant Patients Under ordinary"/>
 <result pre="recipients and those on immunosuppressants are at high risk of" exact="infection" post="due in particular to the suppression of T cell"/>
 <result pre="particular to the suppression of T cell response, making their" exact="susceptibility to" post="SARS-CoV-2 and prognosis, if infected, unclear. On one hand,"/>
 <result pre="On one hand, it has been postulated that reduction of" exact="systemic" post="inflammation by immunosuppressants could improve outcome for COVID-19 patients"/>
 <result pre="a case that immunosuppressed individuals tend to have a higher" exact="viral" post="load, take longer to shed the virus, and may"/>
 <result pre="admitted to hospital with significant progressive pneumonia. The severity of" exact="pneumonia" post="in this group was recorded as greater than their"/>
 <result pre="for 12 days [51,52]. Within this group, there was no" exact="acute" post="renal graft rejection, and all patients eventually recovered from"/>
 <result pre="their infected family members [51]. They attributed the length of" exact="infection" post="but eventual recovery to the hypothesis that long-term immunosuppression"/>
 <result pre="eventual recovery to the hypothesis that long-term immunosuppression might delay" exact="viral" post="clearance and prolong the course of disease but avoid"/>
 <result pre="immunosuppression might delay viral clearance and prolong the course of" exact="disease" post="but avoid fatal pneumonia caused by a hyperimmune response"/>
 <result pre="clearance and prolong the course of disease but avoid fatal" exact="pneumonia" post="caused by a hyperimmune response [51]. Another study of"/>
 <result pre="with other studies, advanced age and comorbidities were associated with" exact="disease" post="severity [7,27,39,40,41]. Type of transplant and time of viral"/>
 <result pre="with disease severity [7,27,39,40,41]. Type of transplant and time of" exact="viral infection" post="after transplant were not statistically significant factors [53]. Laboratory"/>
 <result pre="disease severity [7,27,39,40,41]. Type of transplant and time of viral" exact="infection" post="after transplant were not statistically significant factors [53]. Laboratory"/>
 <result pre="were similar between moderate and severe cases, though albumin was" exact="lower" post="in the severe group [53]. At present there is"/>
 <result pre="was the only marker which differed between moderate and severe" exact="disease" post="and suggested that the chronically immunosuppressed may undergo a"/>
 <result pre="levels of procalcitonin can be a predictor of severe COVID-19" exact="syndrome" post="and potentially related to secondary bacterial infection [54]. From"/>
 <result pre="a predictor of severe COVID-19 syndrome and potentially related to" exact="secondary" post="bacterial infection [54]. From this study there were no"/>
 <result pre="predictor of severe COVID-19 syndrome and potentially related to secondary" exact="bacterial infection" post="[54]. From this study there were no confirmed cases"/>
 <result pre="of severe COVID-19 syndrome and potentially related to secondary bacterial" exact="infection" post="[54]. From this study there were no confirmed cases"/>
 <result pre="[53]. Many epidemiological reports regarding treatment and prognosis of COVID-19" exact="syndrome" post="are based on the general population who would have"/>
 <result pre="the general population who would have had healthy immunity before" exact="viral infection," post="thus overlooking important data for immunocompromised patients [53]. Many"/>
 <result pre="data for immunocompromised patients [53]. Many such patients present with" exact="atypical" post="signs and symptoms leading to missed diagnosis, late presentation,"/>
 <result pre="research into cytokine activation, T cell signalling and migration, and" exact="viral" post="clearance are needed [53]. The postulated anti-inflammatory benefits of"/>
 <result pre="balanced against the possibility of inhibiting anti-viral immunity by delaying" exact="viral" post="shedding and possible organ rejection for those patients having"/>
 <result pre="as not to increase innate immune response, increase likelihood of" exact="autoimmune diseases," post="or further DILI. Vaccinations are costly and usually take"/>
 <result pre="further DILI. Vaccinations are costly and usually take years to" exact="complete" post="stringent animal and human trials before being made available"/>
 <result pre="Some effects seen in previous RNA-based vaccinations have been pancreatitis," exact="lactic acidosis," post="liver steatosis, nerve damage, and death [55]. Liver toxicity"/>
 <result pre="seen in previous RNA-based vaccinations have been pancreatitis, lactic acidosis," exact="liver steatosis," post="nerve damage, and death [55]. Liver toxicity was reported"/>
 <result pre="previous RNA-based vaccinations have been pancreatitis, lactic acidosis, liver steatosis," exact="nerve" post="damage, and death [55]. Liver toxicity was reported in"/>
 <result pre="using RNA therapy for Criglerâ€&quot;Nayjor syndrome, and in an RNA-based" exact="rabies" post="vaccination trial, an increased and deleterious inflammatory response ended"/>
 <result pre="response ended the trial [55]. This is possibly due to" exact="type 1" post="interferon induction by RNA, which is known to induce"/>
 <result pre="1 interferon induction by RNA, which is known to induce" exact="autoimmune diseases" post="[55]. DNA-based vaccines have also been implicated in inducing"/>
 <result pre="6. Conclusions SARS-CoV-2 is a novel coronavirus known to cause" exact="respiratory" post="infections with severity ranging from mild cold- and flu-like"/>
 <result pre="Conclusions SARS-CoV-2 is a novel coronavirus known to cause respiratory" exact="infections" post="with severity ranging from mild cold- and flu-like symptoms"/>
 <result pre="from mild cold- and flu-like symptoms to fatal pneumonia. While" exact="respiratory" post="based, if severe, it can cause dysfunction of other"/>
 <result pre="combination of inflammatory response, sepsis, hypoxia, microthrombotic events, DILI, and" exact="viral" post="damage. Pre-existent liver disease is an independent risk factor"/>
 <result pre="response, sepsis, hypoxia, microthrombotic events, DILI, and viral damage. Pre-existent" exact="liver disease" post="is an independent risk factor of death in SARS-CoV-2"/>
 <result pre="sepsis, hypoxia, microthrombotic events, DILI, and viral damage. Pre-existent liver" exact="disease" post="is an independent risk factor of death in SARS-CoV-2"/>
 <result pre="risk factor of death in SARS-CoV-2 related infection, and severity" exact="of liver" post="damage most likely correlates with COVID-19 disease severity. Nevertheless,"/>
 <result pre="and severity of liver damage most likely correlates with COVID-19" exact="disease" post="severity. Nevertheless, abnormalities in the liver function tests of"/>
 <result pre="in the liver function tests of these patients, without pre-existing" exact="liver disease," post="may have prognostic significance and predict adverse outcomes. Patients"/>
 <result pre="may have prognostic significance and predict adverse outcomes. Patients with" exact="chronic" post="liver disease and in particular those on immunosuppressive therapies"/>
 <result pre="have prognostic significance and predict adverse outcomes. Patients with chronic" exact="liver disease" post="and in particular those on immunosuppressive therapies including liver"/>
 <result pre="prognostic significance and predict adverse outcomes. Patients with chronic liver" exact="disease" post="and in particular those on immunosuppressive therapies including liver"/>
 <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding Conflicts of Interest The authors declare no conflict"/>
 <result pre="LLCBerlin, Germany2015Volume 1282123 5.OtrompkeJ.Investigating treatment strategies for the Middle East" exact="respiratory" post="syndrome coronavirusPharm. J.201429310.1211/pj.2014.20066890 6.World Health Organization2004Available online: https://www.who.int/ith/diseases/sars/en/(accessed on"/>
 <result pre="Germany2015Volume 1282123 5.OtrompkeJ.Investigating treatment strategies for the Middle East respiratory" exact="syndrome" post="coronavirusPharm. J.201429310.1211/pj.2014.20066890 6.World Health Organization2004Available online: https://www.who.int/ith/diseases/sars/en/(accessed on 12"/>
 <result pre="https://www.who.int/ith/diseases/sars/en/(accessed on 12 April 2020) 7.GuanW.-J.NiZ.-Y.HuY.LiangW.-H.OuC.-Q.HeJ.-X.LiuL.ShanH.LeiC.-L.HuiD.S.et al.Clinical Characteristics of Coronavirus" exact="Disease" post="2019 in ChinaN. Engl. J. Med.20203821708172010.1056/NEJMoa200203232109013 8.PengL.LiuJ.XuW.LuoQ.ChenD.LeiZ.HuangZ.LiX.DengK.LinB.et al.SARS-CoV-2 can"/>
 <result pre="anal swabs, and oropharyngeal swabs specimensJ. Med. Virol.202010.1002/jmv.2593632330305 9.ChanJ.F.-W.YuanS.KokK.-H.ToK.K.-W.ChuH.YangJ.XingF.LiuJ.YipC.C.-Y.PoonR.W.-S.et al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="oropharyngeal swabs specimensJ. Med. Virol.202010.1002/jmv.2593632330305 9.ChanJ.F.-W.YuanS.KokK.-H.ToK.K.-W.ChuH.YangJ.XingF.LiuJ.YipC.C.-Y.PoonR.W.-S.et al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="of a family clusterLancet202039551452310.1016/S0140-6736(20)30154-931986261 10.MizumotoK.KagayaK.ZarebskiA.ChowellG.Estimating the asymptomatic proportion of coronavirus" exact="disease" post="2019 (COVID-19) cases on board the Diamond Princess cruise"/>
 <result pre="RioC.Mild or Moderate Covid-19N. Engl. J. Med.202010.1056/nejmcp2009249 12.AronsM.M.HatfieldK.M.ReddyS.C.KimballA.JamesA.JacobsJ.R.TaylorJ.SpicerK.BardossyA.C.OakleyL.P.et al.Presymptomatic SARS-CoV-2" exact="infections" post="and transmission in a skilled nursing facilityN. Engl. J."/>
 <result pre="a skilled nursing facilityN. Engl. J. Med.202010.1056/NEJMoa2008457 13.BaggettT.P.KeyesH.SpornN.GaetaJ.M.Prevalence of SARS-CoV-2" exact="Infection" post="in Residents of a Large Homeless Shelter in BostonJAMA20202710.1001/jama.2020.6887"/>
 <result pre="Homeless Shelter in BostonJAMA20202710.1001/jama.2020.6887 14.WangY.LiuY.LiuL.WangX.LuoN.LingL.Clinical Outcomes in 55 Patients with" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at"/>
 <result pre="Shelter in BostonJAMA20202710.1001/jama.2020.6887 14.WangY.LiuY.LiuL.WangX.LuoN.LingL.Clinical Outcomes in 55 Patients with Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital"/>
 <result pre="in BostonJAMA20202710.1001/jama.2020.6887 14.WangY.LiuY.LiuL.WangX.LuoN.LingL.Clinical Outcomes in 55 Patients with Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission"/>
 <result pre="BostonJAMA20202710.1001/jama.2020.6887 14.WangY.LiuY.LiuL.WangX.LuoN.LingL.Clinical Outcomes in 55 Patients with Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 Who Were Asymptomatic at Hospital Admission in"/>
 <result pre="York CityN. Engl. J. Med.202010.1056/NEJMc201041932302078 17.GiacomelliA.PezzatiL.ContiF.BernacchiaD.SianoM.OreniL.RusconiS.GervasoniC.RidolfoA.L.RizzardiniG.et al.Self-reported Olfactory and Taste" exact="Disorders" post="in Patients with Severe Acute Respiratory Coronavirus 2 Infection:"/>
 <result pre="Med.202010.1056/NEJMc201041932302078 17.GiacomelliA.PezzatiL.ContiF.BernacchiaD.SianoM.OreniL.RusconiS.GervasoniC.RidolfoA.L.RizzardiniG.et al.Self-reported Olfactory and Taste Disorders in Patients with" exact="Severe" post="Acute Respiratory Coronavirus 2 Infection: A Cross-sectional StudyClin. Infect."/>
 <result pre="17.GiacomelliA.PezzatiL.ContiF.BernacchiaD.SianoM.OreniL.RusconiS.GervasoniC.RidolfoA.L.RizzardiniG.et al.Self-reported Olfactory and Taste Disorders in Patients with Severe" exact="Acute" post="Respiratory Coronavirus 2 Infection: A Cross-sectional StudyClin. Infect. Dis.202010.1093/cid/ciaa33032215618"/>
 <result pre="al.Self-reported Olfactory and Taste Disorders in Patients with Severe Acute" exact="Respiratory" post="Coronavirus 2 Infection: A Cross-sectional StudyClin. Infect. Dis.202010.1093/cid/ciaa33032215618 18.SiddiqiH.K.MehraM.R.COVID-19"/>
 <result pre="Differ.2020271451145410.1038/s41418-020-0530-332205856 20.PedersenS.F.HoY.-C.SARS-CoV-2: A storm is ragingJ. Clin. Investig.20201302202220510.1172/JCI13764732217834 21.Giamarellos-BourboulisE.J.NeteaM.G.RovinaN.AkinosoglouK.AntoniadouA.AntonakosN.DamorakiG.GkavogianniT.AdamiM.-E.KatsaounouP.et al.Complex" exact="Immune Dysregulation" post="in COVID-19 Patients with Severe Respiratory FailureCell Host Microbe2020271910.1016/j.chom.2020.04.00931951820"/>
 <result pre="Clin. Investig.20201302202220510.1172/JCI13764732217834 21.Giamarellos-BourboulisE.J.NeteaM.G.RovinaN.AkinosoglouK.AntoniadouA.AntonakosN.DamorakiG.GkavogianniT.AdamiM.-E.KatsaounouP.et al.Complex Immune Dysregulation in COVID-19 Patients with" exact="Severe" post="Respiratory FailureCell Host Microbe2020271910.1016/j.chom.2020.04.00931951820 22.XuL.LiuJ.LuM.YangD.ZhengX.Liver injury during highly pathogenic"/>
 <result pre="Investig.20201302202220510.1172/JCI13764732217834 21.Giamarellos-BourboulisE.J.NeteaM.G.RovinaN.AkinosoglouK.AntoniadouA.AntonakosN.DamorakiG.GkavogianniT.AdamiM.-E.KatsaounouP.et al.Complex Immune Dysregulation in COVID-19 Patients with Severe" exact="Respiratory" post="FailureCell Host Microbe2020271910.1016/j.chom.2020.04.00931951820 22.XuL.LiuJ.LuM.YangD.ZhengX.Liver injury during highly pathogenic human"/>
 <result pre="Gastroenterol. Hepatol.2020542843010.1016/S2468-1253(20)30057-132145190 24.XieH.ZhaoJ.LianN.LinS.XieQ.ZhuoH.Clinical characteristics of non-ICU hospitalized patients with coronavirus" exact="disease" post="2019 and liver injury: A retrospective studyLiver Int.202010.1111/liv.14449 25.ChaiX.HuL.ZhangY.HanW.LuZ.KeA.ZhouJ.ShiG.FangN.FanJ.et"/>
 <result pre="ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV" exact="Infection" post="2020BioRxiv202010.1101/2020.02.03.931766 26.YeoC.KaushalS.YeoD.Enteric involvement of coronaviruses: Is faecalâ€&quot;oral transmission of"/>
 <result pre="2019 Coronavirus DiseaseJ. Clin. Transl. Hepatol.20208131710.14218/JCTH.2020.0001932274341 28.BoettlerT.NewsomeP.N.MondelliM.U.MaticicM.CorderoE.CornbergM.BergT.Care of patients with" exact="liver disease" post="during the COVID-19 pandemic: EASL-ESCMID position paperJHEP Rep.2020210011310.1016/j.jhepr.2020.10011332289115 29.FanZ.ChenL.LiJ.TianC.ZhangY.HuangS.LiuZ.ChengJ.Clinical"/>
 <result pre="Coronavirus DiseaseJ. Clin. Transl. Hepatol.20208131710.14218/JCTH.2020.0001932274341 28.BoettlerT.NewsomeP.N.MondelliM.U.MaticicM.CorderoE.CornbergM.BergT.Care of patients with liver" exact="disease" post="during the COVID-19 pandemic: EASL-ESCMID position paperJHEP Rep.2020210011310.1016/j.jhepr.2020.10011332289115 29.FanZ.ChenL.LiJ.TianC.ZhangY.HuangS.LiuZ.ChengJ.Clinical"/>
 <result pre="and the liver: Little cause for concernLancet Gastroenterol. Hepatol.2020552953010.1016/S2468-1253(20)30084-432203680 31.WeberS.MayerleJ.IrlbeckM.GerbesA.L.Severe" exact="liver failure" post="during SARS-CoV-2 infectionGut202010.1136/gutjnl-2020-321350 32.LiY.XieZ.LinW.CaiW.WenC.GuanY.MoX.WangJ.WangY.PengP.et al.An exploratory randomized, controlled study"/>
 <result pre="on the efficacy and safety of lopinavir/ritonavir or arbidol treating" exact="adult" post="patients hospitalized with mild/moderate COVID-19 (ELACOI) 2020MedRxiv202010.1101/2020.03.19.20038984 33.LeeW.M.Drug-Induced HepatotoxicityN."/>
 <result pre="35.EbertE.C.Hypoxic Liver InjuryMayo Clinic ProceedingsElsevier BVAmsterdam, The Netherlands2006Volume 8112321236 36.SpieziaL.BoscoloA.PolettoF.CerrutiL.TiberioI.CampelloE.NavalesiP.SimioniP.COVID-19-Related" exact="Severe" post="Hypercoagulability in Patients Admitted to Intensive Care Unit for"/>
 <result pre="Liver InjuryMayo Clinic ProceedingsElsevier BVAmsterdam, The Netherlands2006Volume 8112321236 36.SpieziaL.BoscoloA.PolettoF.CerrutiL.TiberioI.CampelloE.NavalesiP.SimioniP.COVID-19-Related Severe" exact="Hypercoagulability" post="in Patients Admitted to Intensive Care Unit for Acute"/>
 <result pre="Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for" exact="Acute" post="Respiratory FailureThromb. Haemost.202010.1055/s-0040-1710018 37.YinS.HuangM.LiD.TangN.Difference of coagulation features between severe"/>
 <result pre="Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute" exact="Respiratory" post="FailureThromb. Haemost.202010.1055/s-0040-1710018 37.YinS.HuangM.LiD.TangN.Difference of coagulation features between severe pneumonia"/>
 <result pre="Acute Respiratory FailureThromb. Haemost.202010.1055/s-0040-1710018 37.YinS.HuangM.LiD.TangN.Difference of coagulation features between severe" exact="pneumonia" post="induced by SARS-CoV2 and non-SARS-CoV2J. Thromb. Thrombolysis20201410.1007/s11239-020-02105-8 38.RanucciM.BallottaA.Di DeddaU.BayshnikovaE.PoliM.D.RestaM.FalcoM.AlbanoG.MenicantiL.The"/>
 <result pre="Thromb. Thrombolysis20201410.1007/s11239-020-02105-8 38.RanucciM.BallottaA.Di DeddaU.BayshnikovaE.PoliM.D.RestaM.FalcoM.AlbanoG.MenicantiL.The procoagulant pattern of patients with COVID-19" exact="acute" post="respiratory distress syndromeJ. Thromb. Haemost.202010.1111/jth.1485432302448 39.LiuY.LiangX.XuX.DongM.JiaS.LuC.WeiY.Increased Serum Alkaline Phosphatase"/>
 <result pre="Thrombolysis20201410.1007/s11239-020-02105-8 38.RanucciM.BallottaA.Di DeddaU.BayshnikovaE.PoliM.D.RestaM.FalcoM.AlbanoG.MenicantiL.The procoagulant pattern of patients with COVID-19 acute" exact="respiratory" post="distress syndromeJ. Thromb. Haemost.202010.1111/jth.1485432302448 39.LiuY.LiangX.XuX.DongM.JiaS.LuC.WeiY.Increased Serum Alkaline Phosphatase in"/>
 <result pre="syndromeJ. Thromb. Haemost.202010.1111/jth.1485432302448 39.LiuY.LiangX.XuX.DongM.JiaS.LuC.WeiY.Increased Serum Alkaline Phosphatase in Patients with" exact="Acute" post="Ischemic StrokeJ. Stroke Cerebrovasc. Dis.201928212510.1016/j.jstrokecerebrovasdis.2018.09.01130268369 40.ParkJ.-B.KangD.-Y.YangH.-M.ChoH.-J.ParkK.LeeH.-Y.KangH.-J.KooB.-K.KimH.-S.Serum alkaline phosphatase is"/>
 <result pre="Cerebrovasc. Dis.201928212510.1016/j.jstrokecerebrovasdis.2018.09.01130268369 40.ParkJ.-B.KangD.-Y.YangH.-M.ChoH.-J.ParkK.LeeH.-Y.KangH.-J.KooB.-K.KimH.-S.Serum alkaline phosphatase is a predictor of mortality," exact="myocardial infarction," post="or stent thrombosis after implantation of coronary drug-eluting stentEur."/>
 <result pre="phosphatase is a predictor of mortality, myocardial infarction, or stent" exact="thrombosis" post="after implantation of coronary drug-eluting stentEur. Heart J.20123492093110.1093/eurheartj/ehs41923242189 41.LiuJ.WangD.LiJ.XiongY.LiuB.WeiC.WuS.LinJ.LiuM.Increased"/>
 <result pre="infarction, or stent thrombosis after implantation of coronary drug-eluting stentEur." exact="Heart" post="J.20123492093110.1093/eurheartj/ehs41923242189 41.LiuJ.WangD.LiJ.XiongY.LiuB.WeiC.WuS.LinJ.LiuM.Increased Serum Alkaline Phosphatase as a Predictor of"/>
 <result pre="J.20123492093110.1093/eurheartj/ehs41923242189 41.LiuJ.WangD.LiJ.XiongY.LiuB.WeiC.WuS.LinJ.LiuM.Increased Serum Alkaline Phosphatase as a Predictor of Symptomatic" exact="Hemorrhagic" post="Transformation in Ischemic Stroke Patients with Atrial Fibrillation and/or"/>
 <result pre="Predictor of Symptomatic Hemorrhagic Transformation in Ischemic Stroke Patients with" exact="Atrial Fibrillation" post="and/or Rheumatic Heart DiseaseJ. Stroke Cerebrovasc. Dis.2016252448245210.1016/j.jstrokecerebrovasdis.2016.06.01727425768 42.WilliamsonE.WalkerA.J.BhaskaranK.BaconS.BatesC.MortonC.E.CurtisH.J.MehrkarA.EvansD.InglesbyP.et al.OpenSAFELY:"/>
 <result pre="of Symptomatic Hemorrhagic Transformation in Ischemic Stroke Patients with Atrial" exact="Fibrillation" post="and/or Rheumatic Heart DiseaseJ. Stroke Cerebrovasc. Dis.2016252448245210.1016/j.jstrokecerebrovasdis.2016.06.01727425768 42.WilliamsonE.WalkerA.J.BhaskaranK.BaconS.BatesC.MortonC.E.CurtisH.J.MehrkarA.EvansD.InglesbyP.et al.OpenSAFELY:"/>
 <result pre="Transformation in Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic" exact="Heart" post="DiseaseJ. Stroke Cerebrovasc. Dis.2016252448245210.1016/j.jstrokecerebrovasdis.2016.06.01727425768 42.WilliamsonE.WalkerA.J.BhaskaranK.BaconS.BatesC.MortonC.E.CurtisH.J.MehrkarA.EvansD.InglesbyP.et al.OpenSAFELY: Factors associated with"/>
 <result pre="death in the linked electronicMedRxiv202010.1101/2020.05.06.20092999 43.PrinsG.H.OlingaP.Potential implications of COVID-19 in" exact="non-alcoholic fatty liver" post="diseaseLiver Int.202010.1111/liv.14484 44.VaduganathanM.VardenyO.MichelT.McMurrayJ.J.V.PfefferM.A.SolomonS.Reninâ€&quot;Angiotensinâ€&quot;Aldosterone System Inhibitors in Patients with Covid-19N."/>
 <result pre="in the linked electronicMedRxiv202010.1101/2020.05.06.20092999 43.PrinsG.H.OlingaP.Potential implications of COVID-19 in non-alcoholic" exact="fatty liver" post="diseaseLiver Int.202010.1111/liv.14484 44.VaduganathanM.VardenyO.MichelT.McMurrayJ.J.V.PfefferM.A.SolomonS.Reninâ€&quot;Angiotensinâ€&quot;Aldosterone System Inhibitors in Patients with Covid-19N."/>
 <result pre="System Inhibitors in Patients with Covid-19N. Engl. J. Med.20203821653165910.1056/NEJMsr200576032227760 45.AdamsD.H.HÃ¼bscherS.G.Systemic" exact="viral" post="infections and collateral damage in the liverAm. J. Pathol.20061681057105910.2353/ajpath.2006.05129616565481"/>
 <result pre="Inhibitors in Patients with Covid-19N. Engl. J. Med.20203821653165910.1056/NEJMsr200576032227760 45.AdamsD.H.HÃ¼bscherS.G.Systemic viral" exact="infections" post="and collateral damage in the liverAm. J. Pathol.20061681057105910.2353/ajpath.2006.05129616565481 46.British"/>
 <result pre="2020) 50.MehtaP.McAuleyD.F.BrownM.SanchezE.TattersallR.S.MansonJ.J.COVID-19: Consider cytokine storm syndromes and immunosuppressionLancet20203951033103410.1016/S0140-6736(20)30628-032192578 51.ZhuL.GongN.LiuB.LuX.ChenD.ChenS.ShuH.MaK.XuX.GuoZ.et al.Coronavirus" exact="Disease" post="2019 Pneumonia in Immunosuppressed Renal Transplant Patients: A summary"/>
 <result pre="Consider cytokine storm syndromes and immunosuppressionLancet20203951033103410.1016/S0140-6736(20)30628-032192578 51.ZhuL.GongN.LiuB.LuX.ChenD.ChenS.ShuH.MaK.XuX.GuoZ.et al.Coronavirus Disease 2019" exact="Pneumonia" post="in Immunosuppressed Renal Transplant Patients: A summary of 10"/>
 <result pre="syndromes and immunosuppressionLancet20203951033103410.1016/S0140-6736(20)30628-032192578 51.ZhuL.GongN.LiuB.LuX.ChenD.ChenS.ShuH.MaK.XuX.GuoZ.et al.Coronavirus Disease 2019 Pneumonia in Immunosuppressed" exact="Renal" post="Transplant Patients: A summary of 10 confirmed cases in"/>
 <result pre="US epicenterArab. Archaeol. Epigr.202010.1111/ajt.15941 54.LippiG.PlebaniM.Procalcitonin in patients with severe coronavirus" exact="disease" post="2019 (COVID-19): A meta-analysisClin. Chim. Acta202050519019110.1016/j.cca.2020.03.00432145275 55.LurieN.SavilleM.HatchettR.HaltonJ.Developing Covid-19 Vaccines"/>
 <result pre="with elevated alanine transaminase (ALT), gamma-glutamyl transferase (GGT), bilirubin, and" exact="monocyte" post="chemoattractant protein 1 (MCP1). Taken together with lower levels"/>
 <result pre="bilirubin, and monocyte chemoattractant protein 1 (MCP1). Taken together with" exact="lower" post="levels of albumin, this points to liver damage with"/>
 <result pre="seen mainly in patients at the severe end of the" exact="disease" post="spectrum. pathogens-09-00430-t001_Table 1Table 1 Liver enzyme abnormalities in COVID-19"/>
 <result pre="disease spectrum. pathogens-09-00430-t001_Table 1Table 1 Liver enzyme abnormalities in COVID-19" exact="disease" post="vary and reflect the degree of inflammatory response, direct"/>
 <result pre="response, direct biliary injury by the virus, the presence or" exact="absence of" post="ischemia/microthromboses, and possible drug-induced liver injury. Hypoalbuminaemia and high"/>
 <result pre="with poor prognosis. Albumin Transaminases GGT Bilirubin Alkaline Phosphatase COVID-19" exact="Severe" post="liver injury from inflammatory response (cytokine storm) Variable Variable"/>
</results>
